In recent years, Brain-Computer Interface (BCI) technology has advanced rapidly, transitioning from laboratory research to clinical and consumer applications, marking what many in the industry describe as a ‘golden era’ of development. This momentum is driven by supportive government policies, surging investment, technological breakthroughs, and expanding use cases. Since 2023, multiple Chinese provinces and cities have introduced specialized policies to promote brain science and brain-inspired intelligence, with BCI officially designated as a key focus area for future industries at the national level. Globally, tech pioneers such as Neuralink and Synchron, alongside Chinese companies like BrainCo and BrainTop, have achieved significant milestones—some products are already in clinical trials or have received medical device certifications. BCI shows immense potential in medical rehabilitation (e.g., enabling paralyzed patients to control exoskeletons), treatment of neurological disorders (such as epilepsy and depression), human-computer interaction, and even the metaverse. Experts predict that with continuous improvements in algorithms, signal acquisition accuracy, and evolving ethical and regulatory frameworks, the BCI industry will achieve large-scale commercialization within the next 5 to 10 years, becoming a critical convergence point between artificial intelligence and life sciences.
近年来，脑机接口（Brain-Computer Interface, BCI）技术迅猛发展，正逐步从实验室走向临床与消费市场，被业界广泛视为进入‘黄金发展期’。政策支持、资本涌入、技术突破和应用场景拓展共同推动了这一趋势。2023年以来，中国多个省市相继出台支持脑科学与类脑智能发展的专项政策，国家层面也将脑机接口列为未来产业重点方向之一。与此同时，全球科技巨头如Neuralink、Synchron以及国内企业如脑陆科技、强脑科技等纷纷取得关键性进展，部分产品已进入临床试验或获得医疗器械认证。脑机接口在医疗康复（如帮助瘫痪患者控制外骨骼）、神经疾病治疗（如癫痫、抑郁症干预）、人机交互乃至元宇宙等领域展现出巨大潜力。专家预测，随着算法优化、信号采集精度提升及伦理法规逐步完善，脑机接口产业将在未来5–10年内实现规模化商用，成为人工智能与生命科学融合的重要突破口。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8585.html